Brought to you by 
Sale of debt nets $727.5mm for BioMarin Pharmaceutical
17 Oct 2013
Executive Summary
Rare disease drug developer BioMarin Pharmaceutical Inc. netted $727.5mm (including the overallotment) through the sale of debt. It offered $375mm of five-year 0.75% senior subordinated notes and $375mm of seven-year 1.50% senior subordinated notes. The notes convert into 10.62 shares per $1k prinicipal amount, equal to $94.15 per share (the current market average is $73.12) and interest is payable semi-annually on April 15 and October 15 each year, starting in 2014.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Convertible Debt
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sale of debt nets $727.5mm for BioMarin Pharmaceutical
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice